{"id":"cyclophosphamide-vindelsine-cytarabine-doxorubincin-prednisone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Infection"},{"rate":"5-10%","effect":"Steroid-induced psychosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"These drugs work by targeting different stages of the cell cycle and DNA replication. Cyclophosphamide and Doxorubicin cause DNA damage, while Cytarabine and Vindelsine interfere with DNA synthesis. Prednisone suppresses the immune system and reduces inflammation.","oneSentence":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Vindelsine is a topoisomerase inhibitor that disrupts DNA replication, Cytarabine is a nucleoside analog that inhibits DNA synthesis, Doxorubicin is an anthracycline antibiotic that intercalates DNA, Prednisone is a corticosteroid that suppresses inflammation and immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:24.505Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia, Acute myeloid leukemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Protocol AA"],"phase":"phase_2","status":"active","brandName":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","genericName":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Vindelsine is a topoisomerase inhibitor that disrupts DNA replication, Cytarabine is a nucleoside analog that inhibits DNA synthesis, Doxorubicin is an anthracycline antibiotic that intercalates DNA, Prednisone is a corticosteroid that suppresses inflammation and immune response. Used for Acute lymphoblastic leukemia, Acute myeloid leukemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}